Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedNov 20, 2025
DataAggregated Company Financials
Companies4
  • 7D-0.3%
  • 3M-0.3%
  • 1Y6.7%
  • YTD15.0%

In the last week, the Biotech industry is flat overall, with Molecular Partners standing out by going down 3.8%. The past year has been better, since the industry has gained 10% in that time. Looking forward, earnings are forecast to grow by 28% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 21 Nov 2025CHF 1.8bCHF 343.6m-CHF 10,514,000.008x-172.1x5.3x
Sun, 19 Oct 2025CHF 2.0bCHF 344.3m-CHF 15,083,000.008.1x-134.6x5.9x
Tue, 16 Sep 2025CHF 1.8bCHF 383.4m-CHF 57,057,000.007.7x-31.5x4.7x
Thu, 14 Aug 2025CHF 2.0bCHF 333.9m-CHF 44,705,000.008.3x-44.3x5.9x
Sat, 12 Jul 2025CHF 2.0bCHF 333.9m-CHF 44,705,000.007.6x-43.7x5.9x
Mon, 09 Jun 2025CHF 1.9bCHF 333.9m-CHF 44,705,000.008x-42.1x5.6x
Wed, 07 May 2025CHF 1.9bCHF 336.6m-CHF 39,259,000.006.9x-47.5x5.5x
Fri, 04 Apr 2025CHF 1.5bCHF 409.3m-CHF 35,110,868.004.8x-43.6x3.7x
Sun, 02 Mar 2025CHF 1.8bCHF 387.3m-CHF 48,828,868.005.3x-37.1x4.7x
Tue, 28 Jan 2025CHF 1.7bCHF 330.3m-CHF 75,131,868.003.1x-22.7x5.2x
Thu, 26 Dec 2024CHF 1.6bCHF 330.9m-CHF 87,805,465.002.2x-18.5x4.9x
Sat, 23 Nov 2024CHF 1.8bCHF 331.2m-CHF 86,988,629.001.5x-20.2x5.3x
Mon, 21 Oct 2024CHF 1.8bCHF 333.1m-CHF 82,023,629.001.8x-21.6x5.3x
Wed, 18 Sep 2024CHF 1.6bCHF 333.6m-CHF 81,088,264.001.7x-19.3x4.7x
Fri, 16 Aug 2024CHF 810.6mCHF 170.7m-CHF 141,356,264.001.9x-5.7x4.7x
Sun, 14 Jul 2024CHF 758.3mCHF 151.7m-CHF 146,197,264.001.4x-5.2x5x
Tue, 11 Jun 2024CHF 624.2mCHF 169.3m-CHF 139,094,874.120.9x-4.5x3.7x
Thu, 09 May 2024CHF 485.7mCHF 171.0m-CHF 134,962,367.901x-3.6x2.8x
Sat, 06 Apr 2024CHF 382.6mCHF 67.4m-CHF 173,193,075.500.1x-2.2x5.7x
Mon, 04 Mar 2024CHF 360.1mCHF 55.6m-CHF 173,212,672.720.2x-2.1x6.5x
Wed, 31 Jan 2024CHF 377.8mCHF 317.6m-CHF 176,007,021.001.1x-2.1x1.2x
Fri, 29 Dec 2023CHF 288.1mCHF 317.2m-CHF 176,181,463.000.6x-1.6x0.9x
Sun, 26 Nov 2023CHF 304.1mCHF 318.1m-CHF 210,673,204.00n/a-1.4x1x
Tue, 24 Oct 2023CHF 252.0mCHF 318.1m-CHF 212,843,042.00n/a-1.2x0.8x
Thu, 21 Sep 2023CHF 274.7mCHF 318.5m-CHF 219,022,560.00n/a-1.3x0.9x
Sat, 19 Aug 2023CHF 509.0mCHF 325.8m-CHF 175,785,222.00n/a-2.9x1.6x
Mon, 17 Jul 2023CHF 315.7mCHF 320.3m-CHF 179,703,342.00n/a-1.8x1x
Wed, 14 Jun 2023CHF 320.9mCHF 333.9m-CHF 181,118,746.00n/a-1.8x1x
Fri, 12 May 2023CHF 369.7mCHF 498.9m-CHF 18,561,621.001.7x-19.9x0.7x
Sun, 09 Apr 2023CHF 407.2mCHF 485.0mCHF 12.4m1.5x32.8x0.8x
Tue, 07 Mar 2023CHF 485.5mCHF 493.4mCHF 14.5m1.7x33.5x1x
Thu, 02 Feb 2023CHF 497.0mCHF 493.4mCHF 14.5m1.6x34.3x1x
Sat, 31 Dec 2022CHF 485.3mCHF 493.4mCHF 14.5m1.7x33.5x1x
Mon, 28 Nov 2022CHF 515.0mCHF 493.4mCHF 14.5m1.7x35.5x1x
Price to Earnings Ratio

35.5x


Total Market Cap: CHF 515.0mTotal Earnings: CHF 14.5mTotal Revenue: CHF 493.4mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average -14.2x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 3.5x is lower than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 11% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-2.23%
Healthcare0.47%
Biotech-0.30%
Biotech-0.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SANN Santhera Pharmaceuticals HoldingCHF 12.3015.2%
+CHF 21.7m		55.7%PS3.4x
IDIA IdorsiaCHF 3.252.5%
+CHF 20.0m		330.4%PS3.5x
KURN Kuros BiosciencesCHF 27.220.8%
+CHF 8.6m		21.5%PS10.3x
BSLN Basilea PharmaceuticaCHF 47.750.8%
+CHF 4.9m		17.8%PE8.1x

Latest News

SANN
CHF 12.30
Santhera Pharmaceuticals Holding
7D
15.2%
1Y
55.7%
IDIA
CHF 3.25
Idorsia
7D
2.5%
1Y
330.4%

IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment

Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.
MOLN
CHF 3.23
Molecular Partners
7D
-1.8%
1Y
-33.0%
BSLN
CHF 47.75
Basilea Pharmaceutica
7D
0.8%
1Y
17.8%
KURN
CHF 27.22
Kuros Biosciences
7D
0.8%
1Y
21.5%

Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts

Oct 18
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
RLF
CHF 2.57
Relief Therapeutics Holding
7D
-12.9%
1Y
-51.6%